Top

Indian Journal of Hematology and Blood Transfusion

Published in:

01-06-2017 | Original Article

Is There a Relationship Between CXCR4 Gene Expression and Prognosis of Immune Thrombocytopenia in Children?

Authors: Sajedeh Saeidi, Javad Mohammadi-Asl, Mohammad Ali Jalali Far, Ali Amin Asnafi, Firouzeh Dehuri, Yousef Tavakolifar, Najmaldin Saki

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 2/2017

Abstract

Immune thrombocytopenia (ITP) is a common autoimmune disorder characterized by decreased platelet count (thrombocytopenia) and bleeding symptoms due to production of autoantibodies against platelets. Chemokines are molecules inducing chemotaxis and play an important role in megakaryopoiesis, including CXCR4 chemokine receptor. CXCR4 is expressed on cells of megakaryocytic series, especially platelets, and triggers several mechanisms in these cells. The purpose of this study was to evaluate the pattern of CXCR4 gene changes upon diagnosis and after treatment and its comparison with laboratory findings in peripheral blood samples from newly diagnosed ITP patients. 35 newly diagnosed patients with ITP and 35 healthy controls were enrolled in this study. CXCR4 gene expression was investigated before and after treatment using real-time PCR. HPRT gene was used as the reference gene to calculate the expression rate of CXCR4 as CXCR4/HPRT ratio. CXCR4 gene expression upon diagnosis and after treatment in peripheral blood plasma of ITP patients showed a significant decrease in comparison with the control group while its expression did not change before and after treatment. No significant correlation was found between the expression of this gene and laboratory parameters. Due to unpredictable course of ITP in patients and the possibility of its progress to refractory form, accurate choice of a biomarker is essential for evaluating prognosis and detection of resistant forms.

Stasi R, Newland AC (2011) ITP: a historical perspective. Br J Haematol 153(4):437–450CrossRefPubMed

Saeidi S, Jaseb K, Asnafi AA, Rahim F, Pourmotahari F, Mardaniyan S et al (2014) Immune thrombocytopenic purpura in children and adults: a comparative retrospective study in Iran. Int J Hematol Oncol Stem Cell Res 8(3):30–36PubMedPubMedCentral

Gu D, Chen Z, Zhao H, Du W, Xue F, Ge J et al (2010) Th1 (CXCL10) and Th2 (CCL2) chemokine expression in patients with immune thrombocytopenia. Hum Immunol 71(6):586–591CrossRefPubMed

Ku FC, Tsai CR, Wang J, Wang CH, Chang TK, Hwang WL (2013) Stromal-derived factor-1 gene variations in pediatric patients with primary immune thrombocytopenia. Eur J Haematol 90(1):25–30CrossRefPubMed

Wang JF, Liu ZY, Groopman JE (1998) The alpha-chemokine receptor CXCR4 is expressed on the megakaryocytic lineage from progenitor to platelets and modulates migration and adhesion. Blood 92(3):756–764PubMed

Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M et al (2009) The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem 55(4):611–622CrossRefPubMed

George JN, Woolf SH, Raskob GE, Wasser J, Aledort L, Ballem P et al (1996) Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 88(1):3–40PubMed

Anoop P (2012) Immune thrombocytopenic purpura: historical perspective, current status, recent advances and future directions. Indian Pediatr 49(10):811–818CrossRefPubMed

Johnsen J (2012) Pathogenesis in immune thrombocytopenia: new insights. ASH Educ Program Book 2012(1):306–312

10.

Zhou B, Zhao H, Yang RC, Han ZC (2005) Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol 54(2):107–116CrossRefPubMed

11.

Wendling F, Han Z-C (1997) 2 Positive and negative regulation of megakaryocytopoiesis. Baillières Clin Haematol 10(1):29–45CrossRefPubMed

12.

Machlus KR, Thon JN, Italiano JE (2014) Interpreting the developmental dance of the megakaryocyte: a review of the cellular and molecular processes mediating platelet formation. Br J Haematol 165(2):227–236CrossRefPubMed

13.

Deutsch VR, Tomer A (2006) Megakaryocyte development and platelet production. Br J Haematol 134(5):453–466CrossRefPubMed

14.

Abi-Younes S, Sauty A, Mach F, Sukhova G, Libby P, Luster A (2000) The stromal cell–derived factor-1 chemokine is a potent platelet agonist highly expressed in atherosclerotic plaques. Circ Res 86(2):131–138CrossRefPubMed

15.

Deutsch V, Bitan M, Friedmann Y, Eldor A, Vlodavsky I (2000) Megakaryocyte maturation is associated with expression of the CXC chemokine connective tissue-activating peptide CTAP III. Br J Haematol 111(4):1180–1189CrossRefPubMed

16.

Gear AR, Camerini D (2003) Platelet chemokines and chemokine receptors: linking hemostasis, inflammation, and host defense. Microcirculation 10(3–4):335–350CrossRefPubMed

17.

Hodohara K, Fujii N, Yamamoto N, Kaushansky K (2000) Stromal cell-derived factor-1 (SDF-1) acts together with thrombopoietin to enhance the development of megakaryocytic progenitor cells (CFU-MK). Blood 95(3):769–775PubMed

18.

Rivière C, Subra F, Cohen-Solal K, Cordette-Lagarde V, Letestu R, Auclair C et al (1999) Phenotypic and functional evidence for the expression of CXCR4 receptor during megakaryocytopoiesis. Blood 93(5):1511–1523PubMed

19.

Labbaye C, Spinello I, Quaranta MT, Pelosi E, Pasquini L, Petrucci E et al (2008) A three-step pathway comprising PLZF/miR-146a/CXCR4 controls megakaryopoiesis. Nat Cell Biol 10(7):788–801CrossRefPubMed

20.

Scaradavou A (2002) HIV-related thrombocytopenia. Blood Rev 16(1):73–76CrossRefPubMed

21.

Feng X, Scheinberg P, Samsel L, Rios O, Chen J, McCOY J et al (2012) Decreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura. J Thromb Haemost 10(8):1616–1623CrossRefPubMedPubMedCentral

22.

Wang A, Guilpain P, Chong BF, Chouzenoux S, Guillevin L, Du Y et al (2010) Dysregulated expression of CXCR4/CXCL12 in subsets of patients with systemic lupus erythematosus. Arthritis Rheum 62(11):3436–3446CrossRefPubMed

23.

Ahn JY, Seo K, Weinberg OK, Arber DA (2013) The prognostic value of CXCR4 in acute myeloid leukemia. Appl Immunohistochem Mol Morphol 21(1):79–84PubMed

24.

Salim JP, Goette NP, Lev PR, Chazarreta CD, Heller PG, Alvarez C et al (2009) Dysregulation of stromal derived factor 1/CXCR4 axis in the megakaryocytic lineage in essential thrombocythemia. Br J Haematol 144(1):69–77CrossRefPubMed

25.

Kowalska MA, Ratajczak J, Hoxie J, Brass LF, Gewirtz A, Poncz M et al (1999) Megakaryocyte precursors, megakaryocytes and platelets express the HIV co-receptor CXCR4 on their surface: determination of response to stromal-derived factor-1 by megakaryocytes and platelets. Br J Haematol 104(2):220–229CrossRefPubMed

26.

Wang J-D, Ou T-T, Wang C-J, Chang T-K, Lee H-J (2010) Platelet apoptosis resistance and increased CXCR4 expression in pediatric patients with chronic immune thrombocytopenic purpura. Thromb Res 126(4):311–318CrossRefPubMed

27.

Olsson B, Ridell B, Carlsson L, Jacobsson S, Wadenvik H (2008) Recruitment of T cells into bone marrow of ITP patients possibly due to elevated expression of VLA-4 and CX3CR1. Blood 112(4):1078–1084CrossRefPubMed

28.

Pitchford SC, Lodie T, Rankin SM (2012) VEGFR1 stimulates a CXCR4-dependent translocation of megakaryocytes to the vascular niche, enhancing platelet production in mice. Blood 120(14):2787–2795CrossRefPubMed

29.

Janz JM, Ren Y, Looby R, Kazmi MA, Sachdev P, Grunbeck A et al (2011) Direct interaction between an allosteric agonist pepducin and the chemokine receptor CXCR4. J Am Chem Soc 133(40):15878–15881CrossRefPubMed

Title: Is There a Relationship Between CXCR4 Gene Expression and Prognosis of Immune Thrombocytopenia in Children?
Authors: Sajedeh Saeidi
Javad Mohammadi-Asl
Mohammad Ali Jalali Far
Ali Amin Asnafi
Firouzeh Dehuri
Yousef Tavakolifar
Najmaldin Saki
Publication date: 01-06-2017
Publisher: Springer India
Published in: Indian Journal of Hematology and Blood Transfusion / Issue 2/2017
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI: https://doi.org/10.1007/s12288-016-0648-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Increased Level of Factor VIII and Physiological Inhibitors of Coagulation in Patients with Sickle Cell Disease

Facts and Fallacies of Kidd Antibodies: Experience in a Tertiary Care Hospital in North India

Enoxaparin Induced Skin Lesions in Pregnancy: A Rare But Clinically Recognizable Association

Assessment of Heart and Liver Iron Overload in Thalassemia Major Patients Using T2* Magnetic Resonance Imaging

Evaluation of Bone Marrow Microvessel Density in Patients with Aplastic Anemia

Patterns of Adverse Transfusion Reactions in a Tertiary Care Centre of North India: A Step Towards Hemovigilance

Keynote webinar | Spotlight on antibody–drug conjugates in cancer